AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34247026 — intervention group
Group type: EXPERIMENTAL
Intervention: HRC display intervention for sepsis
Number of subjects: 0
Study 34332925 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiogram (CTA) prior to surgery
Number of subjects: 37
Study 34332925 — intervention group
Group type: COMPARATOR
Intervention: No imaging
Number of subjects: 37
Study 36396624 — intervention group
Group type: EXPERIMENTAL
Intervention: BiLSTM model
Number of subjects: 878
Study 36396624 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-BiLSTM model
Number of subjects: 878
Study 36396624 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-BiGRU model
Number of subjects: 878
Study 33087119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg every 4 weeks (Q4W)
Number of subjects: 0
Study 33087119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg Q4W
Number of subjects: 0
Study 33087119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33087119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0
Study 35296984 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer recovery coach (PRC) intervention
Number of subjects: 193
Study 35296984 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 193
Study 36007755 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 1120858
Study 36007755 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons who utilized TXA consistently (≥90% of cases)
Number of subjects: 1120858
Study 36007755 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not receive TXA
Number of subjects: 1120858
Study 36007755 — intervention group
Group type: COMPARATOR
Intervention: Surgeons who used TXA infrequently (≤30% of cases)
Number of subjects: 1120858
Study 33531453 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 32013655 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient endometrial ablation procedure
Number of subjects: 151
Study 36316073 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-informed stepped care (DiSC) intervention
Number of subjects: 24
Study 36316073 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 24
Study 33740350 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation (RFA)
Number of subjects: 33
Study 32705817 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with vigabatrin (80–150 mg/kg/day)
Number of subjects: 80
Study 32705817 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment of epileptic seizures
Number of subjects: 80
Study 32705817 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with epilepsy (51/80; 63.8%)
Number of subjects: 80
Study 32705817 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population of 80 infants
Number of subjects: 80
Study 34799110 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered crude protein (CP) content in dietary supplements (15.3% during baseline, 19.3% during experimental)
Number of subjects: 6
Study 34799110 — intervention group
Group type: COMPARATOR
Intervention: Regular supplements (13.5% during baseline, 14.8% during experimental)
Number of subjects: 6
Study 33973327 — intervention group
Group type: EXPERIMENTAL
Intervention: RNase1 pretreatment 24 hours before A. hydrophila injection
Number of subjects: 0
Study 33973327 — intervention group
Group type: COMPARATOR
Intervention: Control (injected PBS)
Number of subjects: 0
Study 33973327 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection (A. hydrophila-injected)
Number of subjects: 0
Study 34898088 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation of the pudendal nerve (EAP), 50 min/time, for 12 weeks
Number of subjects: 81
Study 34898088 — intervention group
Group type: COMPARATOR
Intervention: Transrectal pelvic floor biofeedback combined with electrical stimulation, 50 min/time, for 12 weeks
Number of subjects: 81
Study 34311528 — intervention group
Group type: EXPERIMENTAL
Intervention: EPP-AF® 400 mg/day
Number of subjects: 124
Study 34311528 — intervention group
Group type: EXPERIMENTAL
Intervention: EPP-AF® 800 mg/day
Number of subjects: 124
Study 34311528 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study 32028389 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-assisted intervention (GIAI)
Number of subjects: 192
Study 32028389 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 192
Study 35654363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5-mg or 2.0-mg) administered monthly or pro re nata over 24 months
Number of subjects: 349
Study 34173229 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up calls from an ED nurse within 24 h after discharge
Number of subjects: 9836
Study 34173229 — intervention group
Group type: COMPARATOR
Intervention: Scripted satisfaction survey telephone call
Number of subjects: 9836
Study 32926835 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose pneumococcal conjugate vaccine
Number of subjects: 0
Study 32926835 — intervention group
Group type: COMPARATOR
Intervention: Two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine
Number of subjects: 0
Study 35102732 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory plus expiratory neuromuscular electrical stimulation
Number of subjects: 120
Study 35102732 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm pacing (control)
Number of subjects: 120
Study 33222689 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined risk factor and metabolite model
Number of subjects: 9071
Study 33222689 — intervention group
Group type: COMPARATOR
Intervention: Risk factors alone
Number of subjects: 9071
Study 33222689 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent validation in UPBEAT
Number of subjects: 9071
Study 33219500 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises and extensive pre-surgery education
Number of subjects: 60
Study 33219500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic exercises)
Number of subjects: 60
Study 33290891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (multi‐component program including free exercise equipment at home, access to smartphone web‐app, and an online forum)
Number of subjects: 62
Study 33290891 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual routine)
Number of subjects: 62
Study 35034025 — intervention group
Group type: EXPERIMENTAL
Intervention: L-FABP biomarker assay
Number of subjects: 154
Study 35034025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no L-FABP)
Number of subjects: 154
Study 34253048 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior lower extremity revascularization (LER)
Number of subjects: 13885
Study 34253048 — intervention group
Group type: EXPERIMENTAL
Intervention: No prior lower extremity revascularization (LER)
Number of subjects: 13885
Study 33038728 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice Husk Compost (RHC)
Number of subjects: 6
Study 33038728 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice Husk Biochar (RHB)
Number of subjects: 6
Study 33038728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycorrhiza (MR)
Number of subjects: 6
Study 33038728 — intervention group
Group type: EXPERIMENTAL
Intervention: RHB + MR
Number of subjects: 6
Study 33038728 — intervention group
Group type: EXPERIMENTAL
Intervention: RHC + MR
Number of subjects: 6
Study 33038728 — intervention group
Group type: COMPARATOR
Intervention: No bio-fertilizers (NF) with 200 mg kg−1 SDZ
Number of subjects: 6
Study 33038728 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-application of bio-fertilizers and SDZ (100 and 200 mg kg−1)
Number of subjects: 6
Study 33038728 — intervention group
Group type: COMPARATOR
Intervention: 200 mg kg−1 SDZ with no bio-fertilizers
Number of subjects: 6
Study 33941247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaxcards, a vaccination-based educational card game
Number of subjects: 13
Study 32147571 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg/day)
Number of subjects: 422
Study 32147571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 34850160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 104
Study 34850160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 34850160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 104
Study 34850160 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin and Placebo
Number of subjects: 104
Study 32031326 — intervention group
Group type: EXPERIMENTAL
Intervention: NACRT plus TME
Number of subjects: 358
Study 32031326 — intervention group
Group type: COMPARATOR
Intervention: TME alone (non-NACRT)
Number of subjects: 358
Study 35248272 — intervention group
Group type: EXPERIMENTAL
Intervention: IASTM
Number of subjects: 147
Study 35248272 — intervention group
Group type: EXPERIMENTAL
Intervention: CKCMOB (MWM)
Number of subjects: 147
Study 35248272 — intervention group
Group type: COMPARATOR
Intervention: Combination of both MT interventions
Number of subjects: 147
Study 35248272 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 147
Study 35248272 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic balance (YBT-LQ™)
Number of subjects: 147
Study 34105177 — intervention group
Group type: EXPERIMENTAL
Intervention: Casimersen (4, 10, 20, and 30 mg/kg weekly infusions)
Number of subjects: 12
Study 34105177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 32828130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 80
Study 32828130 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 34402872 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin in addition to standard care
Number of subjects: 1000
Study 34402872 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 1000
Study 35193046 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure (SAA)
Number of subjects: 200
Study 35193046 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education (SHE)
Number of subjects: 200
Study 32572862 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior POEM approach
Number of subjects: 111
Study 32572862 — intervention group
Group type: COMPARATOR
Intervention: Posterior POEM approach
Number of subjects: 111
Study 32572862 — intervention group
Group type: COMPARATOR
Intervention: Both anterior and posterior approaches
Number of subjects: 111
Study 32004687 — intervention group
Group type: EXPERIMENTAL
Intervention: HepB (CHO)
Number of subjects: 1163
Study 32004687 — intervention group
Group type: COMPARATOR
Intervention: HepB (SC)
Number of subjects: 1163
Study 35219449 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketamine (0.3 mg kg−1)
Number of subjects: 109
Study 35219449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 32975131 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (15.2 ± 4.5 exercise sessions within 2 h before each night shift)
Number of subjects: 24
Study 32975131 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 32975131 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 24
Study 34844295 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Blade
Number of subjects: 41
Study 34844295 — intervention group
Group type: COMPARATOR
Intervention: MAC
Number of subjects: 41
Study 34506958 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners receive feedback
Number of subjects: 699
Study 34506958 — intervention group
Group type: EXPERIMENTAL
Intervention: Both patients and general practitioners receive feedback
Number of subjects: 699
Study 34506958 — intervention group
Group type: COMPARATOR
Intervention: No one receives feedback
Number of subjects: 699
Study 35505644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol via patient-controlled analgesia (PCA) pump (600 mg daily)
Number of subjects: 100
Study 35505644 — intervention group
Group type: COMPARATOR
Intervention: Intermittent tramadol administration
Number of subjects: 100
Study 32233043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' perceived threat during deployment
Number of subjects: 104
Study 35195722 — intervention group
Group type: EXPERIMENTAL
Intervention: TRACK intervention
Number of subjects: 176
Study 35195722 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 176
Study 34410778 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher general social support
Number of subjects: 157
Study 34410778 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher family support (for mothers)
Number of subjects: 157
Study 34410778 — intervention group
Group type: EXPERIMENTAL
Intervention: College education status (for mothers)
Number of subjects: 157
Study 34410778 — intervention group
Group type: EXPERIMENTAL
Intervention: More partner support (for fathers)
Number of subjects: 157
Study 34941043 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC-aided walking
Number of subjects: 30
Study 34941043 — intervention group
Group type: COMPARATOR
Intervention: Unaided walking
Number of subjects: 30
Study 33570975 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation and treatment-as-usual (TAU)
Number of subjects: 538
Study 33570975 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (TAU)
Number of subjects: 538
Study 33676799 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel-coated coils (0.018-inch hydrogel-coated coils, AZUR 18; Terumo Medical Corporation)
Number of subjects: 77
Study 33676799 — intervention group
Group type: COMPARATOR
Intervention: Nonhydrogel group (bare platinum coils and fibered coils without hydrogel-coated coils)
Number of subjects: 77
Study 33676799 — intervention group
Group type: COMPARATOR
Intervention: Nonhydrogel group
Number of subjects: 77
Study 33676799 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel group
Number of subjects: 77
Study 32186656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg IV on days 0 and 14, 500 mg at months 12 and 18) combined with short-term prednisone regimen
Number of subjects: 47
Study 32186656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 47
Study 32186656 — intervention group
Group type: EXPERIMENTAL
Intervention: PDAI score of 45 or higher and/or persistent anti-DSG1 or anti-DSG3 antibody values at month 3
Number of subjects: 47
Study 32878514 — intervention group
Group type: EXPERIMENTAL
Intervention: M2000 (mannuronic acid) 1000 mg/day (two 500 mg capsules daily)
Number of subjects: 50
Study 32878514 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug (interferon beta‐1a, interferon beta‐1b)
Number of subjects: 50
Study 33357709 — intervention group
Group type: EXPERIMENTAL
Intervention: HFD + OCN (3 μg/bird, 1 time/2 d, i.m.)
Number of subjects: 30
Study 33357709 — intervention group
Group type: COMPARATOR
Intervention: HFD + V
Number of subjects: 30
Study 33357709 — intervention group
Group type: COMPARATOR
Intervention: ND + V
Number of subjects: 30
Study 35738693 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to multiple cues
Number of subjects: 74
Study 35738693 — intervention group
Group type: COMPARATOR
Intervention: Exposure to multiple cues that also explicitly depicted the feared outcome (snake biting someone)
Number of subjects: 74
Study 34525277 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (30-µg doses, two doses at 21 days apart)
Number of subjects: 46429
Study 34525277 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 46429
Study 34525277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46429
Study 33636427 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin and crystalloid
Number of subjects: 304
Study 33636427 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid alone
Number of subjects: 304
Study 35698043 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling based on GATHER principles (4 sessions, 45-60 minutes each for 2 weeks)
Number of subjects: 82
Study 35698043 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 82
Study 35698043 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling based on GATHER principles
Number of subjects: 82
Study 34726606 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical video‐based virtual reality (SVVR) training
Number of subjects: 68
Study 34726606 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 68
Study 32992943 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration group (n = 25)
Number of subjects: 50
Study 32992943 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 25)
Number of subjects: 50
Study 36331844 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cultured epidermal cell suspension
Number of subjects: 30
Study 36331844 — intervention group
Group type: COMPARATOR
Intervention: Automated epidermal harvesting system
Number of subjects: 30
Study 33688916 — intervention group
Group type: EXPERIMENTAL
Intervention: Alopecia severity (varied degrees of alopecia)
Number of subjects: 2015
Study 34954440 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed length-marked VCs (dVCs)
Number of subjects: 137
Study 34954440 — intervention group
Group type: COMPARATOR
Intervention: Simplified length-marked VCs (sVCs)
Number of subjects: 137
Study 34954440 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-assisted guidance technique (GA)
Number of subjects: 137
Study 34954440 — intervention group
Group type: COMPARATOR
Intervention: Standard freehand technique (FH)
Number of subjects: 137
Study 33905913 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help exercise program (ITwC) including flexibility, range-of-motion, and lymphedema exercises, and a self-care education program
Number of subjects: 92
Study 33905913 — intervention group
Group type: COMPARATOR
Intervention: Self-care education program only (Control)
Number of subjects: 92
Study 33905913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis using QLU-C10D to calculate QALYs
Number of subjects: 92
Study 33905913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis using SwalQol
Number of subjects: 92
Study 32442384 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min of stationary cycling at moderate intensity (65%‐75% maximal heart rate)
Number of subjects: 15
Study 32442384 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 15
Study 35352415 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (5000 IU, iv)
Number of subjects: 12
Study 35352415 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 12
Study 33550562 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 930
Study 33550562 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive daytime sleepiness
Number of subjects: 930
Study 33550562 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleeping (PSQI > 5)
Number of subjects: 930
Study 33550562 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 45-54 years
Number of subjects: 930
Study 33550562 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 55 years
Number of subjects: 930
Study 33550562 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight or obese
Number of subjects: 930
Study 33550562 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 930
Study 33550562 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 930
Study 33550562 — intervention group
Group type: EXPERIMENTAL
Intervention: Divorced status
Number of subjects: 930
Study 34882176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightly LBNP (-20 mm Hg)
Number of subjects: 10
Study 34882176 — intervention group
Group type: COMPARATOR
Intervention: No LBNP
Number of subjects: 10
Study 33499911 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based health education intervention delivered by trained female community health volunteers (FCHVs) for 12 months
Number of subjects: 884
Study 33499911 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 884
Study 32507144 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment associated with exercises (OMT/EG)
Number of subjects: 90
Study 32507144 — intervention group
Group type: COMPARATOR
Intervention: Exercises group (EG)
Number of subjects: 90
Study 37086227 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg orally twice daily for 7 days starting immediately post-procedure (group B)
Number of subjects: 139
Study 37086227 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no postprocedure prophylaxis, group A)
Number of subjects: 139
Study 37086227 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg orally twice daily for 7 days (group B)
Number of subjects: 139
Study 37086227 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (group A)
Number of subjects: 139
Study 37086227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavotricuspid isthmus ablation
Number of subjects: 139
Study 37086227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Number of subjects: 139
Study 34284348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich vegetables (NRV)
Number of subjects: 18
Study 34284348 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ)
Number of subjects: 18
Study 34284348 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (placebo)
Number of subjects: 18
Study 34798038 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab 105 mg subcutaneously once every 4 weeks
Number of subjects: 397
Study 34798038 — intervention group
Group type: COMPARATOR
Intervention: Infliximab 5 mg/kg intravenously at 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
Number of subjects: 397
Study 34798038 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Number of subjects: 397